In conclusion, our derived findings reveal that patients who were diagnosed as having DM and were prescribed a DPP-4 inhibitor did not exhibit a relatively high PD risk during the 3-year period for which they were followed up. This evidence concerns the gene DPP4 and Parkinson disease.